GelSana

GelSana

United StatesUnited States
•Series A•Founded 2020•Updated 3w ago
Bio Tech/Life SciencesDefenseHealthtechHealth and wellnessB2B1-5 employees
Female FounderFemale Founder

About

GelSana is a commercial-stage biomaterials company transforming wound care with next-generation polymer technology designed to improve healing and patient outcomes. Our first product CleraFlex launched just a few months ago and already 2026 revenue is exceeding expectations, we have signed our first major distribution agreement with a $450k minimum value over the next two years, and CleraFlex is already under review by Value Analysis Committees at four large hospital systems with strong clinical champions. This product is healing stubborn difficult wounds - it works, and demand is starting to build. To date, we’ve raised more than $6.8M in total funding: $4.3M from investors and $2.5M in non-dilutive grants. GelSana is now raising a $12M Series A to scale commercialization and accelerate growth.

Traction & Metrics

Fundraising

$6.8M

Previous Round

Team

Melissa

Melissa

CEO

Donald

Donald

Chief Commercial Officer

Adam

Adam

Director R&D

Ania

Ania

CFO

Mike

Mike

Board Member

Diana

Diana

Board Member

David

David

Advisor

John

John

Advisor

Lisa

Lisa

Advisor

Products

CleraFlex

CleraFlex

Updates

CleraFlex Launch

CleraFlex Launch

CleraFlex was registered with the FDA and launched into the clinic in April 2026.

First Distribution Agreement Signed

In May 2026, we signed our first major distribution agreement with Juvo Medical. This agreement has a $450k minimum value over the next two years.